Trial Profile
A Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyniamics of CHIR-258 in Subjects With Advanced Solid Tumor Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Jan 2011 New trial record